CLLS vs BLE Comparison

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Blackrock Municipal Income Trust II is a perpetual closed-end municipal bond fund. Its objective is to provide a high current income exempt from federal income taxes. The fund invests a majority of its managed assets in municipal obligations issued by or on behalf of states, territories, and possessions of the United States and their political subdivisions, agencies, or instrumentalities (Municipal Bonds), the interest of which is exempt from regular federal income tax (except that the interest may be subject to the alternative minimum tax).